Form 4: IGM Biosciences Chief Scientific Officer Reports Acquisition and Disposal of Shares
SEC Form 4 Filing
Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports acquiring restricted stock units and stock options while disposing of common stock.
Summary
- On March 12, 2024, Bruce Keyt, the Chief Scientific Officer of IGM Biosciences, engaged in transactions involving the company's stock.
- Keyt acquired 46,250 restricted stock units (RSUs) at a price of $0, with vesting occurring in installments starting June 12, 2024.
- He also acquired options to purchase 92,500 shares of common stock at an exercise price of $9.95, with vesting starting April 12, 2024.
- Keyt disposed of 175,801 shares of common stock.
- Following these transactions, Keyt directly owns 92,500 derivative securities and indirectly owns 4,039 shares through his spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The acquisition of RSUs and options is potentially positive, but the disposal of shares is potentially negative. The overall impact is unclear without further context.
Positives
- The acquisition of RSUs and stock options by the Chief Scientific Officer could be interpreted as a positive sign of confidence in the company's future.
Negatives
- The disposal of 175,801 shares of common stock by the Chief Scientific Officer could be interpreted as a negative signal.
Risks
- The vesting schedules of the RSUs and stock options are contingent upon Keyt remaining a service provider, creating a potential risk if he were to leave the company.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Related Party Transactions
- The reporting person's spouse directly holds 4,039 shares of common stock.
Stakeholder Impact
- Shareholders may react to the reported transactions, potentially influencing the stock price.
- Employees may view the executive's stock transactions as a signal of company performance and stability.
Key Dates
| Date | Description |
|---|---|
| 03/12/2024 | Date of the reported transactions: acquisition of RSUs and stock options, and disposal of common stock. |
| 03/14/2024 | Date of signature on the Form 4 filing. |
| 04/12/2024 | First vesting date for the acquired stock options. |
| 06/12/2024 | First vesting date for the acquired restricted stock units (RSUs). |
| 03/12/2034 | Expiration date for the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.